Bergenbio ASA is a renowned company that embodies values of innovation, integrity, and excellence. With a steadfast corporate philosophy, the company strives to revolutionize cancer treatments through its groundbreaking therapies and innovative research. Bergenbio ASA is dedicated to creating a significant impact in patients' lives by developing precision medicines that target specific cancer cells, leading to improved clinical outcomes. The company's commitment to integrity is reflected in its transparent and responsible approach towards conducting clinical trials and regulatory compliance. Bergenbio ASA's relentless pursuit of excellence and commitment to scientific rigor position it as a prominent player in the field of oncology, making it a trustworthy choice for investors and stakeholders.

Bergenbio ASA is primarily present in Norway, where its headquarters are located. However, the company also operates and has business activities across other regions and countries, including Europe and the United States.

Bergenbio ASA, a leading biotech company, has achieved several significant milestones. The company successfully conducted clinical trials for their innovative cancer treatments, showcasing their commitment to advancing medical breakthroughs. Bergenbio ASA also established strategic partnerships with renowned organizations, facilitating the development and commercialization of their portfolio. Their strong research pipeline, including multiple drug candidates targeting cancer and rare diseases, demonstrates their dedication to improving patient outcomes. The company's collaborations with global experts, regulators, and healthcare providers further solidify their position as a cutting-edge player in the biotech industry. Bergenbio ASA continues to drive scientific advancements and deliver innovative therapies for patients worldwide.

Bergenbio ASA, a renowned Norwegian biotechnology company, has a rich history and background. Established in 2007, the company has been dedicated to developing innovative therapies for cancer treatments. With a strong focus on precision medicine, Bergenbio ASA aims to enhance patient outcomes by targeting specific molecular pathways within the tumor microenvironment. Over the years, the company has made significant strides in its research and development, leveraging its deep understanding of cellular signaling pathways and biomarker identification. Bergenbio ASA's commitment to revolutionizing cancer treatment has gained recognition worldwide, positioning it as a leader in the field.

Some of the main competitors of Bergenbio ASA in the market include Inven2, Targovax, and BerGenBio Inc.

Bergenbio ASA is primarily active in the biotechnology and pharmaceutical industries.

Bergenbio ASA is a biotechnology company with a business model focused on the discovery and development of innovative cancer therapeutics. Their main aim is to develop targeted therapies that can improve the survival and quality of life for cancer patients. By leveraging their deep understanding of the biology of cancer, Bergenbio ASA identifies novel drug candidates and conducts clinical trials to assess their efficacy. With a strong focus on precision medicine, the company aims to provide personalized treatments tailored to individual patients' needs. Bergenbio ASA's business model revolves around leveraging cutting-edge science and technology to develop transformative therapies for cancer management.

P/E-forholdet til Bergenbio A er −71,54.

Bergenbio A KUV er 229 274,70.

AlleAktien kvalitetsscore for Bergenbio A er 1/10.

forventede Bergenbio A omsetningen er 68 670,10 NOK.

forventede Bergenbio A -gevinsten er −220,09 mill. NOK.

Bergenbio ASA is a biopharmaceutical company that focuses on the discovery and development of drugs for cancer and inflammatory diseases. The company's core expertise lies in the identification of biomarkers that enable a deeper understanding of disease processes. By combining technologies such as cell models, molecular imaging, and bioinformatics, the company develops novel therapies and drugs based on these biomarkers. The business model of Bergenbio ASA consists of three main divisions: research and development, partnerships and collaborations, and marketing and sales. The research and development department continuously works on new drugs and therapies to improve the treatment of cancer and inflammatory diseases. The research includes the discovery and validation of target molecules, the formulation and optimization of drug candidates, and the conduct of preclinical and clinical studies. The focus is on the development of oral medications that simplify and improve patient care. Bergenbio ASA also has extensive partnerships and collaborations with national and international research institutions, universities, and companies. These partnerships allow Bergenbio ASA to expand its knowledge and resources and intensify collaboration in the development of new drugs. In addition, distribution and marketing activities are carried out jointly to strengthen the market presence and distribution of Bergenbio ASA products. In the marketing and sales department, the company promotes its products and therapies through business partnerships and acquisitions to expand its portfolio and consolidate its position in the global market. The goal is to enter new markets and regions and enable optimal care for patients with cancer and inflammatory diseases. In terms of products, Bergenbio ASA offers the first orally available Axl inhibitor drug, BGB324, which has been tested in clinical trials for the treatment of lung, pancreatic, and bladder cancers. Another product pipeline includes BGB149, a new drug candidate for the treatment of lung and pancreatic cancer, and BGB601, an oral preparation for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. In summary, Bergenbio ASA is a biopharmaceutical company with a strong focus on research and development. Through partnerships and collaborations, the company deepens its understanding of disease processes and creates new therapeutic approaches. The focus on oral medications and the broad product pipeline enable Bergenbio ASA to improve patient care and successfully develop its business model.

Bergenbio A utbetaler et dividende på 0 NOK fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Bergenbio A eller så utdeler ikke selskapet utbytte.

ISIN-en til Bergenbio A er NO0010650013.

WKN for Bergenbio A er A2DPC0.

Tikkeren til Bergenbio A er BGBIO.OL.

I løpet av de siste 12 månedene utbetalte Bergenbio A et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Bergenbio A sannsynligvis betale et utbytte på 0 NOK.

Utdelingsrendementet til Bergenbio A er for øyeblikket .

Bergenbio A betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Bergenbio A betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 NOK. Dette tilsvarer en utbytteavkastning på 0 %.

Bergenbio A tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Bergenbio A den på 0 NOK, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 NOK i utbytte fra Bergenbio A.

Utdelingene fra Bergenbio A blir betalt ut i NOK.